GlassScriptPhysician profile
Desmond Paul-Coker
NPI 1720340805
$7,355.03
in general payments reported to CMS, 2019-2025
45 companies · $1,800 in 2025
The $1,800 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $948 · 2021: $297 · 2023: $1,288 · 2024: $1,980 · 2025: $1,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,068.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,209.14 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $913.15 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $631.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $564.01 | 2019-2025 | |
| Pfizer INC. | $481.52 | 2021-2025 | |
| Lilly USA, LLC | $437.76 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $437.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $289.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $272.58 | 2019-2024 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.12 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $147.66 | 2019-2023 | Belsomra, Segluromet, Steglatro |
| Janssen Pharmaceuticals, INC | $143.99 | 2019-2020 | |
| Corcept Therapeutics | $135.53 | 2020-2025 | Korlym |
| Lundbeck LLC | $129.40 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $99.07 | 2019-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $93.88 | 2020 | |
| Biocryst US Sales Co., LLC | $88.99 | 2023-2024 | Orladeyo |
| Exact Sciences Corporation | $88.59 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Baxter Healthcare | $84.49 | 2023 | Hillrom - Life 2000 Ventilation System |
| Abbott Laboratories | $71.75 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $65.83 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $63.45 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $53.40 | 2023-2024 | |
| Allergan, INC. | $52.58 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $50.60 | 2021 | |
| Sanofi-Aventis U.S. LLC | $49.11 | 2024-2025 | |
| Medtronic, INC. | $39.58 | 2021-2025 | Inceptiv |
| Otsuka America Pharmaceutical, INC. | $36.00 | 2025 | Rexulti |
| Electromed, INC. | $31.99 | 2023-2024 | Smartvest |
| Abiomed | $29.23 | 2024 | Impella |
| Takeda Pharmaceuticals U.S.A., INC. | $28.08 | 2023-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.06 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.55 | 2024 | Recorlev |
| Qiagen, LLC | $24.14 | 2024 | |
| Eisai INC. | $24.08 | 2020 | |
| Agios Pharmaceuticals, INC. | $24.07 | 2025 | Pyrukynd |
| Pacira Therapeutics, INC. | $20.93 | 2019 | |
| Nevro Corp. | $18.57 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $18.29 | 2023 | Seglentis, Livalo |
| Mylan Specialty L.P. | $17.99 | 2019 | |
| Mannkind Corporation | $16.90 | 2020 | |
| Vanda Pharmaceuticals INC. | $15.55 | 2024 | Ponvory |
| Therapeuticsmd, INC. | $15.23 | 2019 | |
| Dermira, INC. | $14.99 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desmond Paul-Coker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.